<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a 32-year-old man with <z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">secondary antiphospholipid syndrome</z:e> (APS) who received oral anticoagulation with <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi> after <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Conventional monitoring of oral anticoagulation by INR measurement was impaired by coagulation factor inhibition in vitro due to a strong <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The case illustrates that monitoring of oral anticoagulation may require determination of single coagulation factor activities in selected patients with APS </plain></SENT>
</text></document>